T2	Participants 172 224	patients with gastroesophageal reflux disease (GERD)
T1	Participants 475 609	adults with GERD-associated sleep disturbances and moderate-to-severe nighttime heartburn (recorded by patient diary during screening)
T3	Participants 611 722	Patients received oral esomeprazole 40 mg (n = 220) or 20 mg (n = 226) or placebo (n = 229) once daily for 4 wk
